IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v599y2021i7886d10.1038_s41586-021-04065-2.html
   My bibliography  Save this article

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Author

Listed:
  • Yulei Zhao

    (Memorial Sloan Kettering Cancer)

  • Yonina R. Murciano-Goroff

    (Memorial Sloan Kettering Cancer Center)

  • Jenny Y. Xue

    (Memorial Sloan Kettering Cancer
    Weill Cornell–Rockefeller–Sloan Kettering Tri-Institutional MD-PhD Program)

  • Agnes Ang

    (Amgen)

  • Jessica Lucas

    (Memorial Sloan Kettering Cancer)

  • Trang T. Mai

    (Memorial Sloan Kettering Cancer)

  • Arnaud F. Cruz Paula

    (Memorial Sloan Kettering Cancer Center)

  • Anne Y. Saiki

    (Amgen)

  • Deanna Mohn

    (Amgen)

  • Pragathi Achanta

    (Amgen)

  • Ann E. Sisk

    (Memorial Sloan Kettering Cancer Center)

  • Kanika S. Arora

    (Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center)

  • Rohan S. Roy

    (Weill Cornell–Rockefeller–Sloan Kettering Tri-Institutional MD-PhD Program)

  • Dongsung Kim

    (Memorial Sloan Kettering Cancer)

  • Chuanchuan Li

    (Memorial Sloan Kettering Cancer)

  • Lee P. Lim

    (Resolution Bioscience)

  • Mark Li

    (Resolution Bioscience)

  • Amber Bahr

    (Memorial Sloan Kettering Cancer Center)

  • Brian R. Loomis

    (Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center)

  • Elisa Stanchina

    (Memorial Sloan Kettering Cancer Center)

  • Jorge S. Reis-Filho

    (Memorial Sloan Kettering Cancer Center)

  • Britta Weigelt

    (Memorial Sloan Kettering Cancer Center)

  • Michael Berger

    (Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center)

  • Gregory Riely

    (Memorial Sloan Kettering Cancer Center)

  • Kathryn C. Arbour

    (Memorial Sloan Kettering Cancer Center)

  • J. Russell Lipford

    (Amgen)

  • Bob T. Li

    (Memorial Sloan Kettering Cancer Center)

  • Piro Lito

    (Memorial Sloan Kettering Cancer
    Memorial Sloan Kettering Cancer Center
    Weill Cornell–Rockefeller–Sloan Kettering Tri-Institutional MD-PhD Program
    Weill Cornell Medical College)

Abstract

Inactive state-selective KRAS(G12C) inhibitors1–8 demonstrate a 30–40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class mutant GTPase inhibitors remains under investigation. Here we evaluated matched pre-treatment and post-treatment specimens from 43 patients treated with the KRAS(G12C) inhibitor sotorasib. Multiple treatment-emergent alterations were observed across 27 patients, including alterations in KRAS, NRAS, BRAF, EGFR, FGFR2, MYC and other genes. In preclinical patient-derived xenograft and cell line models, resistance to KRAS(G12C) inhibition was associated with low allele frequency hotspot mutations in KRAS(G12V or G13D), NRAS(Q61K or G13R), MRAS(Q71R) and/or BRAF(G596R), mirroring observations in patients. Single-cell sequencing in an isogenic lineage identified secondary RAS and/or BRAF mutations in the same cells as KRAS(G12C), where they bypassed inhibition without affecting target inactivation. Genetic or pharmacological targeting of ERK signalling intermediates enhanced the antiproliferative effect of G12C inhibitor treatment in models with acquired RAS or BRAF mutations. Our study thus suggests a heterogenous pattern of resistance with multiple subclonal events emerging during G12C inhibitor treatment. A subset of patients in our cohort acquired oncogenic KRAS, NRAS or BRAF mutations, and resistance in this setting may be delayed by co-targeting of ERK signalling intermediates. These findings merit broader evaluation in prospective clinical trials.

Suggested Citation

  • Yulei Zhao & Yonina R. Murciano-Goroff & Jenny Y. Xue & Agnes Ang & Jessica Lucas & Trang T. Mai & Arnaud F. Cruz Paula & Anne Y. Saiki & Deanna Mohn & Pragathi Achanta & Ann E. Sisk & Kanika S. Arora, 2021. "Diverse alterations associated with resistance to KRAS(G12C) inhibition," Nature, Nature, vol. 599(7886), pages 679-683, November.
  • Handle: RePEc:nat:nature:v:599:y:2021:i:7886:d:10.1038_s41586-021-04065-2
    DOI: 10.1038/s41586-021-04065-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-021-04065-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/s41586-021-04065-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Irati Macaya & Marta Roman & Connor Welch & Rodrigo Entrialgo-Cadierno & Marina Salmon & Alba Santos & Iker Feliu & Joanna Kovalski & Ines Lopez & Maria Rodriguez-Remirez & Sara Palomino-Echeverria & , 2023. "Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    2. Panayiotis Anastasiou & Christopher Moore & Sareena Rana & Mona Tomaschko & Claire E. Pillsbury & Andrea Castro & Jesse Boumelha & Edurne Mugarza & Sophie Carné Trécesson & Ania Mikolajczak & Cristina, 2024. "Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    3. Dan Lu & Yuan Chen & Min Jiang & Jie Wang & Yiting Li & Keke Ma & Wenqiao Sun & Xing Zheng & Jianxun Qi & Wenjing Jin & Yu Chen & Yan Chai & Catherine W. H. Zhang & Hao Liang & Shuguang Tan & George F, 2023. "KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    4. Haochen Zhang & Elias-Ramzey Karnoub & Shigeaki Umeda & Ronan Chaligné & Ignas Masilionis & Caitlin A. McIntyre & Palash Sashittal & Akimasa Hayashi & Amanda Zucker & Katelyn Mullen & Jungeui Hong & A, 2023. "Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    5. Chi Zhou & Wenxin Li & Zhenxing Liang & Xianrui Wu & Sijing Cheng & Jianhong Peng & Kaixuan Zeng & Weihao Li & Ping Lan & Xin Yang & Li Xiong & Ziwei Zeng & Xiaobin Zheng & Liang Huang & Wenhua Fan & , 2024. "Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
    6. Hidenori Kitai & Philip H. Choi & Yu C. Yang & Jacob A. Boyer & Adele Whaley & Priya Pancholi & Claire Thant & Jason Reiter & Kevin Chen & Vladimir Markov & Hirokazu Taniguchi & Rui Yamaguchi & Hiromi, 2024. "Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    7. Marie-Julie Nokin & Alessia Mira & Enrico Patrucco & Biagio Ricciuti & Sophie Cousin & Isabelle Soubeyran & Sonia San José & Serena Peirone & Livia Caizzi & Sandra Vietti Michelina & Aurelien Bourdon , 2024. "RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    8. Johanna Lilja & Jasmin Kaivola & James R. W. Conway & Joni Vuorio & Hanna Parkkola & Pekka Roivas & Michal Dibus & Megan R. Chastney & Taru Varila & Guillaume Jacquemet & Emilia Peuhu & Emily Wang & U, 2024. "SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    9. Ashenafi Bulle & Peng Liu & Kuljeet Seehra & Sapana Bansod & Yali Chen & Kiran Zahra & Vikas Somani & Iftikhar Ali Khawar & Hung-Po Chen & Paarth B. Dodhiawala & Lin Li & Yutong Geng & Chia-Kuei Mo & , 2024. "Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:599:y:2021:i:7886:d:10.1038_s41586-021-04065-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.